Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial

Diabetes Obes Metab. 2023 Oct;25(10):3064-3067. doi: 10.1111/dom.15180. Epub 2023 Jun 29.

Authors

Affiliations

¹ Steno Diabetes Center Copenhagen, Herlev, Denmark.
² Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands.
³ Ziekenhuis Groep Twente, Almelo, The Netherlands.
⁴ Bethesda Diabetes Research Center, Hoogeveen, The Netherlands.
⁵ Department of Internal Medicine, University of Groningen, Groningen, The Netherlands.
⁶ University of Copenhagen, Copenhagen, Denmark.

PMID: 37385968
DOI: 10.1111/dom.15180

No abstract available

Keywords: SGLT2 inhibitor; clinical trial; diabetes complications; diabetic neuropathy; empagliflozin; linagliptin.

Publication types

Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Benzhydryl Compounds*
Cross-Over Studies
Diabetes Mellitus, Type 1*
Diabetic Neuropathies* / drug therapy
Humans
Hypoglycemic Agents
Linagliptin* / therapeutic use
Telmisartan / therapeutic use

Substances

baricitinib
Benzhydryl Compounds
empagliflozin
Hypoglycemic Agents
Linagliptin
Telmisartan